Chlorambucil (Leukeran)

Subscribe to Selected New Research on Chlorambucil

1060 relevant articles (107 outcomes, 140 trials/studies) found for this Drug

Description: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)

Also Known As:

Leukeran; 4-(Bis(2-chloroethyl)amino)benzenebutanoic Acid; Amboclorin; CB-1348; Chloraminophene; Chlorbutin; Glaxo Wellcome Brand of Chlorambucil; GlaxoSmithKline Brand of Chlorambucil; Lympholysin; N,N-Di-(2-chloroethyl)-p-aminophenylbutyric Acid; NSC-3088; Wellcome Brand of Chlorambucil; CB 1348; CB1348; NSC 3088; NSC3088; Benzenebutanoic acid, 4-(bis(2-chloroethyl)amino)-

Relationship Network

Drug Context: Research Results

Organic Chemicals: 42

Hydrocarbons: 362

Halogenated Hydrocarbons: 31

Mustard Compounds: 3

Nitrogen Mustard Compounds: 1

chlorambucil-docosahexaenoic acid conjugate: 11

chlorambucil-arachidonic acid conjugate: 6

VAB-III protocol: 5

chlorambucil-tertiary butyl ester: 2

3,3-difluorochlorambucil: 1

aminochlorambucil: 1

chlorambucil N-oxide: 1

chlorambucil-N-(2-(4-(4-bis(2-chloroethyl)aminophenyl)butyryl)aminoethyl)-5-(4-amidinophenyl)-2-furancarboxamide hydrochloride: 1

chlorambucil-oleic acid conjugate: 1

chlorambucil-spermidine conjugate: 1

chlorambucil-taurocholate: 1

MDC protocol: 1

OPEC protocol 2: 1

1,3-dipalmitoyl-2-(4-(bis(2-chloroethyl)amino)benzenebutanoyl)glycerol

17-hydroxy-3-aza-A-homo-4-androsten-4-one (4-(bis(2-chloroethyl)amino)phenyl)butyrate

17-hydroxy-4-aza-A-nor-5-androsten-3-one (4-N,N-bis(2-chloroethylamino)phenyl)butyrate

3,4-dehydrochlorambucil

3-hydroxy-13,17-seco-5-androsten-17-oic-13,17-lactam (4-(bis(2-chloroethyl)amino)phenyl)butyrate

3-hydroxy-13,17-secoandrostan-17-oic-13,17-lactam (4-(bis(2-chloroethyl)amino)phenyl)butyrate

APC protocol

CHIVPP protocol

chlorambucil half mustard

Experts

1.	Robak, Tadeusz: 3 articles (12/2007 - 07/2005)
2.	Skotnicki, Aleksander B: 2 articles (12/2007 - 10/2005)
3.	German Low-Grade Lymphoma Study Group: 2 articles (01/2007 - 09/2006)
4.	Dörken, B: 2 articles (01/2007 - 06/2002)
5.	Callea, Vincenzo: 2 articles (11/2006 - 02/2002)
6.	Jackson, G H: 2 articles (11/2006 - 01/2000)
7.	Angus, B: 2 articles (11/2006 - 01/2000)
8.	Proctor, S J: 2 articles (11/2006 - 01/2000)
9.	Stelitano, Caterina: 2 articles (11/2006 - 02/2002)
10.	Morabito, Fortunato: 2 articles (11/2006 - 02/2002)

Related Diseases

1.	Nephrotic Syndrome (Syndrome, Nephrotic) 06/01/2000 - "The patient with over 100 relapses of minimal change nephrotic syndrome: prolonged complete remission after chlorambucil treatment." 02/01/1978 - "The data indicate that a stable dosage regimen for chlorambucil is as effective as an increasing dose regimen in achieving long-term remission of frequently relapsing nephrotic syndrome." 01/01/1978 - "Controlled trial of chlorambucil in frequently relapsing nephrotic syndrome in children (a preliminary report)." 04/01/2006 - "Chlorambucil therapy in children with steroid-resistant nephrotic syndrome." 10/01/1992 - "Two men were treated for a nephrotic syndrome with high-dose chlorambucil therapy; 6.5 and 14 years later, respectively, both were azoospermic with high plasmatic FSH values. " Order ALL the reference details at left...
2.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/01/1980 - "Forty patients with lymphocytic lymphoma were treated with escalating doses of chlorambucil biweekly starting at a dose of 0.4 mg/kg. Fifty percent of patients achieved a complete remission, usually after 6-12 months of therapy. " 02/01/2009 - "The overall remission rate was 59% in a prospective, randomized study of untreated patients with chronic lymphocytic leukemia, which was significantly greater than the rate of 26% in the chlorambucil control arm (P < 0.001). " 05/01/1956 - "Early experience with p-(N, N-di-2-chloroethyl)-aminophenylbutyric acid (CB 1348), a new chemotherapeutic agent effective in the treatment of chronic lymphocytic leukemia." 03/01/2003 - "[Effect of chlorambucil on B-lymphocytes in the peripheral blood of patients with chronic lymphocytic leukemia--study of cellular ultrastructure]" 07/01/1999 - "The efficiency of Chlorambucil in the induction of apoptosis was investigated in the study, and measurable apoptosis parameters were compared to the other prognostic factors with the aim of possible prediction of clinical response to the therapy in the patients with CD5 + B-cell chronic lymphocytic leukemia (B-CLL). " Order ALL the reference details at left...
3.	Membranous Glomerulonephritis (Membranous Nephropathy) 11/01/1999 - "We conclude that steroid therapy alone, or associated with chlorambucil, is effective in patients with stage II to III membranous nephropathy. " 01/01/1983 - "Controlled trial of monthly alternated courses of steroid and chlorambucil for idiopathic membranous nephropathy." 01/01/2009 - "Efficacy and safety of low-dose chlorambucil in nephrotic patients with idiopathic membranous nephropathy." 01/01/2001 - "Severe bone marrow failure associated with the use of alternating steroid with chlorambucil in lupus membranous nephropathy in Chinese." 06/01/1996 - "Complete remission of nephrotic syndrome after steroid-chlorambucil in a previous failed short-term steroidal treatment of a primary membranous nephropathy." Order ALL the reference details at left...
4.	Neoplasms (Cancer) 11/11/2000 - "Clinical efficacy of alkylating anticancer drugs, such as chlorambucil, is often limited by the emergence of drug resistant tumor cells. " 08/09/2004 - "An anti-cancer drug (chlorambucil, CLB), which can form an inclusion complex with beta-CD, was selected for loading and in vitro release studies. " 12/01/2000 - "A morphological study of the effect of chlorambucil during the S and G2 phases of the cell cycle of synchronized HEp-2 cancer cell populations using computerized morphometry." 09/01/2009 - "Preparation and bioevaluation of a 99mTc-labeled chlorambucil analog as a tumor targeting agent." 08/06/2008 - "These results suggest that CHL-PE could be an effective parenteral carrier for chlorambucil delivery in cancer treatment." Order ALL the reference details at left...
5.	Hodgkin Disease (Hodgkin's Disease) 08/01/1957 - "Therapeutic results in treatment of Hodgkin's disease with CB 1348 and R-48." 06/01/1956 - "Evaluation of CB 1348 in Hodgkin's disease and allied disorders." 01/01/2008 - "Chlorambucil has been used for treatment of B cell chronic lymphocytic leukemia, non-Hodgkin's and Hodgkin's disease. " 01/01/1960 - "Clinical and haematological observations in lymphoma patients (Hodgkin's disease, Brill-Symmer's disease, lymphogenous leukaemia) treated with N N Di-2-chloroethyl gamma-P-aminophenyl butiric acid (amboclorin)." 09/01/2008 - "In patients with MALT primary lung non-Hodgkin's lymphomas, the recommended first-line therapy should include chlorambucil, CHOP, CHOP-like or fludarabine-containing regimens (grade B). " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Prednisone (Sone)
2.	Cyclophosphamide (Cytoxan)
3.	Methylprednisolone
4.	Prednisolone (Predate)
5.	Vincristine (Oncovin)
6.	Procarbazine (Matulane)
7.	fludarabine
8.	Vinblastine (Vinblastine Sulfate)
9.	Doxorubicin (Adriamycin)
10.	Adrenal Cortex Hormones (Corticosteroids)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Combination Drug Therapy (Combination Chemotherapy)
3.	Aftercare (After-Treatment)
4.	Plasmapheresis
5.	Adjuvant Chemotherapy

Best Treatments:
Research Summary Report
on Nephrotic Syndrome

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 577 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>